Clinical Application of Stereotactic Body Radiotherapy Combined with Deep Hyperthermia in Advanced Liver Cancer
Objective To investigate the efficacy and toxicity of stereotactic body radiotherapy combined with deep hyperthermia in the treatment of advanced liver cancer.Methods A total of 33 patients with advanced liver cancer admitted to Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine from June 2020 to February 2022 were collected and treated with stereotactic body radiotherapy combined with deep hyperthermia.The clinical efficacy,survival and side effects of the patients were analyzed.Results There were 32 patients who could be evaluated for efficacy,including 1 case(3.13％)of CR,24 cases(75.00％)of PR,4 cases(12.50％)of SD and 3 cases(9.38％)of PD,with RR of 78.13％and DCR of 90.63％.The overall survival time of 32 patients was 5-26 months,the median overall survival time was 12.6 months,and the 1-year overall survival rate was 81.25％.The common side effects were hematological toxicity and gastrointestinal reactions,most of which were mild to moderate,and there was no treatment-related death.Conclusion Stereotactic body radiotherapy combined with deep hyperthermia is effective and safe in the treatment of advanced liver cancer,which is expected to make up for the deficiency caused by single radiotherapy.
Advanced liver cancerStereotactic body radiotherapyDeep hyperthermia
国家科技期刊平台
NSTL
万方数据
